NYMC Faculty Publications
Nilotinib-Associated Destructive Thyroiditis
Author Type(s)
Faculty
DOI
10.1155/2015/736092
Journal Title
Case Reports in Endocrinology
First Page
736092
Last Page
736092
Document Type
Article
Publication Date
1-1-2015
Department
Medicine
Disciplines
Medicine and Health Sciences
Abstract
Protein tyrosine kinase inhibitors are currently an important drug class in the treatment of leukemia. They represent targeted cancer therapy and have become the treatment of choice in chronic myeloid leukemia. Tyrosine kinases are enzymes expressed in multiple tissues and are involved in several signaling pathways influencing cellular growth. Below we describe a patient who developed an unusual complication of tyrosine kinase inhibitor therapy: thyrotoxicosis due to destructive thyroiditis. We review the pathophysiology of tyrosine kinase inhibitor-induced thyroid dysfunction particularly with regard to new second-generation tyrosine kinase inhibitors.
Recommended Citation
Bakerywala, S., Schwarcz, M., Goldberg, M. D., Valiquette, G., & Weiss, I. A. (2015). Nilotinib-Associated Destructive Thyroiditis. Case Reports in Endocrinology, 2015, 736092-736092. https://doi.org/10.1155/2015/736092
